nicotinamide-beta-riboside and Parkinson-Disease

nicotinamide-beta-riboside has been researched along with Parkinson-Disease* in 3 studies

Trials

2 trial(s) available for nicotinamide-beta-riboside and Parkinson-Disease

ArticleYear
NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease.
    Nature communications, 2023, Nov-28, Volume: 14, Issue:1

    Nicotinamide adenine dinucleotide (NAD) replenishment therapy using nicotinamide riboside (NR) shows promise for Parkinson's disease (PD) and other neurodegenerative disorders. However, the optimal dose of NR remains unknown, and doses exceeding 2000 mg daily have not been tested in humans. To evaluate the safety of high-dose NR therapy, we conducted a single-center, randomized, placebo-controlled, double-blind, phase I trial on 20 individuals with PD, randomized 1:1 on NR 1500 mg twice daily (n = 10) or placebo (n = 10) for four weeks. The trial was conducted at the Department of Neurology, Haukeland University Hospital, Bergen, Norway. The primary outcome was safety, defined as the frequency of moderate and severe adverse events. Secondary outcomes were tolerability defined as frequency of mild adverse events, change in the whole blood and urine NAD metabolome, and change in the clinical severity of PD, measured by MDS-UPDRS. All 20 participants completed the trial. The trial met all prespecified outcomes. NR therapy was well tolerated with no moderate or severe adverse events, and no significant difference in mild adverse events. NR therapy was associated with clinical improvement of total MDS-UPDRS scores. However, this change was also associated with a shorter interval since the last levodopa dose. NR greatly augmented the blood NAD metabolome with up to 5-fold increase in blood NAD

    Topics: Double-Blind Method; Humans; NAD; Niacinamide; Parkinson Disease; Pyridinium Compounds

2023
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.
    Cell metabolism, 2022, 03-01, Volume: 34, Issue:3

    Topics: Dietary Supplements; Humans; NAD; Niacinamide; Parkinson Disease; Pyridinium Compounds

2022

Other Studies

1 other study(ies) available for nicotinamide-beta-riboside and Parkinson-Disease

ArticleYear
The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson's Disease.
    Cell reports, 2018, 06-05, Volume: 23, Issue:10

    While mitochondrial dysfunction is emerging as key in Parkinson's disease (PD), a central question remains whether mitochondria are actual disease drivers and whether boosting mitochondrial biogenesis and function ameliorates pathology. We address these questions using patient-derived induced pluripotent stem cells and Drosophila models of GBA-related PD (GBA-PD), the most common PD genetic risk. Patient neurons display stress responses, mitochondrial demise, and changes in NAD+ metabolism. NAD+ precursors have been proposed to ameliorate age-related metabolic decline and disease. We report that increasing NAD+ via the NAD+ precursor nicotinamide riboside (NR) significantly ameliorates mitochondrial function in patient neurons. Human neurons require nicotinamide phosphoribosyltransferase (NAMPT) to maintain the NAD+ pool and utilize NRK1 to synthesize NAD+ from NAD+ precursors. Remarkably, NR prevents the age-related dopaminergic neuronal loss and motor decline in fly models of GBA-PD. Our findings suggest NR as a viable clinical avenue for neuroprotection in PD and other neurodegenerative diseases.

    Topics: Animals; Autophagy; Disease Models, Animal; Dopaminergic Neurons; Drosophila melanogaster; Endoplasmic Reticulum Stress; Glucosylceramidase; Humans; Induced Pluripotent Stem Cells; Mitochondria; Mitochondrial Dynamics; Motor Activity; NAD; Neurons; Niacinamide; Parkinson Disease; Pyridinium Compounds; Unfolded Protein Response

2018